Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Pelago Bioscience and Sygnature Discovery collaborate to Provide CETSA® based Target Engagement Assays

Sygnature Discovery today announced that it will collaborate with Pelago Bioscience, a Swedish biotech company to provide target engagement assays with Pelago’s patented Cellular Thermal Shift Assay (CETSA®) method.

While target engagement has long been recognised as pivotal to targeted drug efficacy. Pelago’s CETSA method adds a new dimension to this valuable assay, as it enables measurements to be made within cellular systems. For the first time researchers can now measure directly how a compound interacts with its target within the cell and even within patient tissue. Furthermore the CETSA MS method enables the systemic effects of a drug within the cell to be explored, by measuring its impact on up to 7000 key proteins. Such quantification of the physiologically relevant form of the target in live cells and tissue samples, will accelerate and improve the discovery of high quality drugs.

The collaboration between Sygnature and Pelago will enable more pharmaceutical R&D and biotech companies to incorporate CETSA within their drug discovery process, and will allow the development new and better drugs more quickly and cost-effectively. Specifically, the collaboration will effectively facilitate the integration of CETSA assays for hit confirmation, lead profiling and biomarker discovery in Sygnature projects. Likewise, Pelago customers will have the opportunity to access the full value chain service portfolio at Sygnature.

“We are excited about the opportunity of adding our CETSA target engagement quantifications to projects in the Sygnature portfolio” said Dr Michael Dabrowski, CEO of Pelago Bioscience. “This collaboration, with a UK based service provider will enable more CETSA data to benefit existing and new customers.”

“The CETSA platform is a valuable addition and highly complementary to our own assay platforms and capabilities,” said Dr Paul Clewlow, Senior Vice President, Business Development at Sygnature Discovery, “We believe that the CETSA platform can be rapidly integrated and deliver detailed target engagement information to our clients to inform their discovery programs.”

For more information
Pelago Bioscience AB, Dr Michael Dabrowski, CEO, Tel. +46 (0)730 715 334,
Sygnature Discovery Limited, Dr Paul Clewlow, Senior Vice President, Business Development, Tel: +44 (0)115 9415401,

Latest News

View All

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’

Sygnature Discovery acquires Peak Proteins

Paper on drug discovery equipment

500 – and counting!

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.